Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-302 + Ranibizumab vs Ranibizumab in Neovascular AMD
2024-512879-13-00Phase 3Completed
- Sponsor
- Opthea Limited
- Start
- Sep 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing OPT-302 + Ranibizumab with Ranibizumab alone (2 arms). Primary endpoint: Mean change from baseline to Week 52 in ETDRS BCVA letters. Started Sep 2024; status: completed.
02
Drugs
soziniberceptranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-512879-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512879-13-00.